Ahmed Mohamed Elsharkawy1, Carolyn Miller2, Andrea Hearn3, Gertrud Buerstedde4, Ashley Price5,6, Stuart McPherson2,6. 1. Liver Unit, University Hospitals Birmingham, Birmingham, UK. 2. Liver Unit, Freeman Hospital, Newcastle Upon Tyne, UK. 3. Plummer Court Addiction Service, Newcastle upon Tyne, UK. 4. Bridge View Drug Treatment Centre, Newcastle upon Tyne, UK. 5. Department of Infectious Diseases, Royal Victoria Infirmary, Newcastle Upon Tyne, UK. 6. Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK.
Abstract
BACKGROUND: Chronic hepatitis C infection (HCV) is common in injecting drug users and is a major cause of liver disease. Antiviral treatment can 'cure' HCV, but is frequently associated with side effects and requires regular monitoring. Non-attendance at hospital appointments is frequent. To try and improve attendance and increase the number of current and previous injecting drug users treated we developed three outreach clinics. OBJECTIVE: To review the outcome of patients referred to the outreach clinics. METHODS: Retrospective service review of three clinics at drug treatment centres in Newcastle and Northumberland. Data was collected on attendance rates, patient demographics, treatment rates and outcomes. RESULTS: 141 referrals were received across the three sites with an overall attendance rate of 75% (106 patients, 79% men and median age 36), which compared favourably with that at our hospital (50%). All patients were on methadone/subutex. 45% were infected with Genotype 1 HCV. 10% were cirrhotic. To date, 30% have started treatment and 21% are waiting to start or are still in workup. 13% elected to delay treatment due to early stage disease and 11% were not ready for treatment on psychological or social grounds. Only 12% failed to attend follow up after initial assessment. To date, 24 patients have completed full courses of treatment with sustained viral response in 13 patients. Results are awaited for seven patients. CONCLUSIONS: The development of outreach clinics for HCV in drug treatment centres can substantially improve clinic attendance and increase access to treatment in this marginalised group.
BACKGROUND:Chronic hepatitis C infection (HCV) is common in injecting drug users and is a major cause of liver disease. Antiviral treatment can 'cure' HCV, but is frequently associated with side effects and requires regular monitoring. Non-attendance at hospital appointments is frequent. To try and improve attendance and increase the number of current and previous injecting drug users treated we developed three outreach clinics. OBJECTIVE: To review the outcome of patients referred to the outreach clinics. METHODS: Retrospective service review of three clinics at drug treatment centres in Newcastle and Northumberland. Data was collected on attendance rates, patient demographics, treatment rates and outcomes. RESULTS: 141 referrals were received across the three sites with an overall attendance rate of 75% (106 patients, 79% men and median age 36), which compared favourably with that at our hospital (50%). All patients were on methadone/subutex. 45% were infected with Genotype 1 HCV. 10% were cirrhotic. To date, 30% have started treatment and 21% are waiting to start or are still in workup. 13% elected to delay treatment due to early stage disease and 11% were not ready for treatment on psychological or social grounds. Only 12% failed to attend follow up after initial assessment. To date, 24 patients have completed full courses of treatment with sustained viral response in 13 patients. Results are awaited for seven patients. CONCLUSIONS: The development of outreach clinics for HCV in drug treatment centres can substantially improve clinic attendance and increase access to treatment in this marginalised group.
Entities:
Keywords:
Chronic Hepatitis; Chronic Viral Hepatitis; Hcv; Hepatitis C
Authors: A J Freeman; G J Dore; M G Law; M Thorpe; J Von Overbeck; A R Lloyd; G Marinos; J M Kaldor Journal: Hepatology Date: 2001-10 Impact factor: 17.425
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: F Degos; C Christidis; N Ganne-Carrie; J P Farmachidi; C Degott; C Guettier; J C Trinchet; M Beaugrand; S Chevret Journal: Gut Date: 2000-07 Impact factor: 23.059
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: Stuart McPherson; Shion Gosrani; Sarah Hogg; Preya Patel; Aaron Wetten; Rachael Welton; Kate Hallsworth; Matthew Campbell Journal: BMJ Open Gastroenterol Date: 2020-08